• Biologics represent some of the most expensive drugs in the US. The introduction of a pathway for biosimilars in 2010 has not resulted in the competition and cost savings many had hoped for.

• Which is the biggest barrier to biosimilars:
  • Patents and litigation?
  • Trade secrets that prevent “recipes” for production from being shared?
  • Distrust of biosimilars among patients and physicians?

• Is Dr. Peter Bach right? Should we give up on biosimilars?